19 May 2013
Keywords: roche, xeloda, effective, adjuvant, therapy, colon, cancer
Article | 21 June 2004
Data reported at the annual meeting of the American Society of Clinical Oncology in New Orleans suggest that Roche's Xeloda ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 June 2004
17 May 2013
© 2013 thepharmaletter.com